Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Robert S. Mansbach"'
Autor:
Karen Joy Shaw, Min Hee Lee, Padmaja Paderu, Cristina Jiménez-Ortigosa, Steven Park, Yanan Zhao, Annie Lee, David S. Perlin, Robert S. Mansbach
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
APX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections. The half-life of APX001A, the active moiety of APX001, is signific
Autor:
Yanan, Zhao, Min Hee, Lee, Padmaja, Paderu, Annie, Lee, Cristina, Jimenez-Ortigosa, Steven, Park, Robert S, Mansbach, Karen Joy, Shaw, David S, Perlin
Publikováno v:
Antimicrobial agents and chemotherapy. 62(10)
APX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections. The half-life of APX001A, the active moiety of APX001, is signific
Autor:
Kerri A. Schoedel, Robert S. Mansbach
Publikováno v:
Pharmaceutical Medicine. 29:141-153
Prescription drugs with actions in the central nervous system (CNS) can produce effects on mood, perception, cognition, behavior, and brain reward processes that can result in pleasurable intoxication and subsequent drug-seeking behavior, and in some
Publikováno v:
Drug and Alcohol Dependence. 112:173-177
The scientific and regulatory assessment of abuse and dependence potential of drugs involves a multi-layered evaluation of its properties related to chemistry, formulation, pharmacology, animal behavior and clinical response. In addition to the prima
Publikováno v:
Behavioural Pharmacology. 18:731-743
Development of N-methyl-D-aspartate (NMDA) antagonists for a variety of disorders has been hindered by their production of phencyclidine (PCP)-like psychological effects and abuse potential. There is, however, evidence to suggest that this problem mi
Autor:
Jack E. Henningfield, Charles Grudzinskas, Eric C. Strain, Robert S. Mansbach, Cynthia G. McCormick, Chris Ellyn Johanson, C. Wright, Roland R. Griffiths, Charles W. Gorodetzky, Sidney H. Schnoll, Robert L. Balster
Publikováno v:
Drug and Alcohol Dependence. 83:S77-S82
A scientific meeting was held in April 2005 to consider how the formulation of medications might impact on their potential for abuse. The background papers prepared for this meeting, as well as abstracts of volunteered presentations, are published in
Publikováno v:
Drug and Alcohol Dependence. 83:S15-S22
The availability of increasingly sophisticated drug formulations and delivery devices has created new opportunities in drug development. These newer approaches can result in improved drug bioavailability, or they can alter key pharmacokinetic paramet
Autor:
Thomas I. Davis, Carol B. Fox, Michael C. Wirtz, Michael G. Vetelino, F. David Tingley, Krista E. Bianco, Robert S. Mansbach, David W. Schulz, Jotham Wadsworth Coe, Crystal G. Bashore, Hans Rollema, Eric P. Arnold, Paige Roanne Palmer Brooks, Steven B. Sands, Brian T. O’Neill, Lorraine A. Lebel
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 15:4889-4897
3,5-Bicyclic aryl piperidines are a new class of high-affinity alpha4beta2 nicotinic receptor agents. We have sought nicotinic receptor partial agonists of the alpha4beta2 nicotinic acetylcholine receptor for smoking cessation, and a number of compou
Autor:
Yi Lu, Jotham Wadsworth Coe, Thomas I. Davis, David W. Schulz, Lorraine A. Lebel, Robert S. Mansbach, Paige Roanne Palmer Brooks, Michael C. Wirtz, Alka Shrikhande, Michael G. Vetelino, Leslie K. Chambers, Eric P. Arnold, Eric Schaeffer, Brian T. O’Neill, Steven B. Sands, and F. David Tingley, James Heym, Carol B. Fox, Huang Jianhua, Charles C. Rovetti, Hans Rollema
Publikováno v:
Modern Drug Synthesis
Herein we describe a novel series of compounds from which varenicline (1, 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine) has been identified for smoking cessation. Neuronal nicotinic acetylcholine receptors (nAChRs) mediate the dep
Publikováno v:
Drug and Alcohol Dependence. 70:S73-S85
Evaluation of abuse liability is one of many obligations incurred by industrial sponsors in the development of medications acting on substrates in the central nervous system. In addition to providing the information necessary for a scheduling recomme